BI-WEEKLY TAXOL & RT IN ANDROGEN ABLATED ADVANCED PROSTATE CANCER

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这是一项研究前列腺癌治疗的方案，其中对雄激素消融的前列腺癌进行确定性放疗，并添加赫赛汀。先前的研究表明，雄激素阻断，在许多情况下，显着减少肿瘤体积，与辐射相结合，是显着优于辐射单独在减少局部进展和无病生存的措施。然而，结果并不理想，因为在许多患者中很难检测到进展，只能通过PSA升高来指示。需要更多的方法。赫赛汀是一种靶向Her-2/神经受体的人源化单克隆抗体，已在乳腺癌中显示出前景。雄激素消融可诱导Her 2/neu过表达（不良结局），并引起放射增敏，导致更好的局部控制和无病生存（理想结局）。赫赛汀通过与受体结合，可能干扰Her-2/neu的表达，因此是有益的。这项剂量递增的I期研究增加了低剂量（在队列中逐步增加）的泰素每周两次被认为是手术切除的晚期患者，通常接受雄激素消融和放射治疗。除了放射增敏作用外，这些剂量的紫杉醇几乎不会增加毒性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a protocol to study the treatment of prostate cancer with definitive radiotherapy applied to androgen-ablated prostate cancer, with the addition of Herceptin. Prior studies have revealed that androgen blockade, which significantly reduces tumor volume in many cases, in combination with radiation is significantly better than radiation alone in measures on decrease in local progression and disease-free survival. Results are less than optimal, however, since progression is hard to detect in many patients and may only be indicated by a rise in PSA. Additional methodologies are required. Herceptin is a humanized monoclonal antibody that targets the Her-2/neuroreceptor and has shown promise in breast cancer. Androgen ablation could induce Her2/neu overexpression (an undesirable outcome) and cause radiosensitization resulting in better local control and disease-free survival (a desirable outcome). Herceptin, by binding to the receptor, may interfere with the expression of Her-2/neu and therefore be of benefit. This dose-escalation phase-I study adds low doses (increasing stepwise in cohorts) of Taxol twice a week to patients deemed too advanced for surgical resection and who are usually treated with androgen ablation and radiation. Taxol at these doses should add little toxicity, except through radiosensitization.